Last reviewed · How we verify
VC005 groups
At a glance
| Generic name | VC005 groups |
|---|---|
| Sponsor | Jiangsu vcare pharmaceutical technology co., LTD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo (PHASE2)
- Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. (PHASE3)
- Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis (PHASE2)
- Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis (PHASE3)
- Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis (PHASE1)
- Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. (PHASE2)
- Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VC005 groups CI brief — competitive landscape report
- VC005 groups updates RSS · CI watch RSS
- Jiangsu vcare pharmaceutical technology co., LTD portfolio CI